Clinical Trials Browser

NCT03776812 2025-10-07

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

178 enrolled 21 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

613 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04068896 2025-05-29

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Phase 1/2 Completed

89 enrolled 21 charts

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT01220154 2025-02-21

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Phase 1 Completed

9 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT03246074 2024-10-24

Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer

Phase 1 Completed

35 enrolled 16 charts

Gynecologic

Ovarian Neoplasms

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Phase 2 Recruiting

40 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT02117817 2022-07-28

Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer

Phase 1 Withdrawn

Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

NCT05310344 2022-04-04

Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

Phase 2 Unknown

50 enrolled

Gynecologic

Ovarian Neoplasms

NCT04815408 2021-03-25

PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

Phase 2 Unknown

40 enrolled

Gynecologic

Ovarian Neoplasms

NCT04590625 2020-10-19

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Phase 2 Unknown

58 enrolled

Gynecologic

Ovarian Neoplasms

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Phase 1 Completed

169 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

NCT00407407 2019-10-18